Recombinant vaccine-induced protection against the highly pathogenic Simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure

Journal of Virology

Volumn 72, Issue 5, 1998, Pages 4170-4182

  Benson, J ^a   Chougnet, C ^a   Robert Guroff, M ^a   Montefiori, D ^b   Markham, P ^c   Shearer, G ^a   Gallo, R C ^a,d   Cranage, M ^e   Paoletti, E ^f   Limbach, K ^f   Venzon, D ^a   Tartaglia, J ^f   Franchini, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f Virogenetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; POL PROTEIN; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENVELOPE GENE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; INOCULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL GENE; VERO CELL; VIREMIA; VIRUS ATTENUATION; VIRUS PATHOGENESIS;

EID: 18344405225     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.5.4170-4182.1998     Document Type: Article

References (50)

1. Abimiku, A. G., G. Franchini, J. Tartaglia, K. Aldrich, M. Myagkikh, P. D. Markham, P. Chong, M. Klein, M. P. Kieny, E. Paoletti, R. C. Gallo, and M. Robert-Garoff. 1995. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat. Med. 1:321-329.
2. mac251-infected macaques previously immunized with NYVAC-SIV vaccines. J. Acquired Immune Defic. Syndr. 15:S78-S85.
3. Afonso, L. C. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
4. Andersson, S., B. Makitalo, R. Thorstensson, G. Franchini, J. Tartaglia, K. Limbach, E. Paoletti, P. Putkonen, and G. Biberfeld. 1996. Immunogenicity and protective efficacy of an HIV-2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J. Infect. Dis. 174:977-985.
5. Baba, T. W., Y. S. Jeong, D. Pennick, R. Bronson, M. F. Greene, and R. M. Ruprecht 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825.
6. Boom, R., C. J. A. Sol, M. M. M. Salimans, C. L. Jansen, P. M. E. Wertheim-Van Dillen, and J. Van Der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
7. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:S26-S32.
8. Cadoz, M., A. Strady, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti, and S. Plotkin. 1992. Immunisation with canarypox virus expressing rabies glycoproteins. Lancet 339:1429-1432.
9. Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Posppíšil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869-879.
10. Clark, S. C., S. K. Arya, F. Wong-Staal, M. Matsumoto-Kobayashi, R. M. Kay, R. J. Kaufman, E. L. Brown, C. Shoemaker, T. Copeland, S. Oroszlan, K. Smith, M. G. Sarngadharan, S. G. Linder, and R. C. Gallo. 1984. Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal leukemic cells. Proc. Natl. Acad. Sci. USA 81:2543-2547.
11. Cooney, E. L. 1993. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a compound vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp 160 protein. Proc. Natl. Acad. Sci. USA 90:1882-1886.
12. Cranage, M. P., A. Baskerville, L. A. E. Ashworth, M. Dennis, N. Cook, R. Cook, S. A. Sharpe, J. Rose, P. Kitchin, and P. J. Greenaway. 1992. Mucosal infection and vaccine studies with macaque SIV. Vaccine Res. 1:311-318.
13. Daniel, M. D., G. P. Mazzara, M. A. Simon, P. K. Sehgal, T. Kodama, D. L. Panicali, and R. C. Desrosiers. 1994. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res. Hum. Retroviruses 10:839-851.
14. Davis, L., P. Lipsky, and K. Bottomly. 1995. Measurement of human and murine interleukin 2 and interleukin 4, p. 6.3.1-6.3.13. In J. Coligan et al. (ed.), Current protocols in immunology. Green Publishing and Wiley-Interscience, New York, N.Y.
15. Desrosiers, R. C. 1995. Non-human primate models for AIDS vaccines. AIDS 9(Suppl. A):S137-S141.
16. Excler, J.-L., and S. Plotkin. 1997. The prime-boost concept applied to HIV preventive vaccines. AIDS 11(Suppl. A):S127-S137.
17. Franchini, G., C. Gurgo, H. G. Guo, R. C. Gallo, E. Collalti, K. A. Fargnoli, L. F. Hall, F. Wong-Staal, and M. S. Reitz, Jr. 1987. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature 328:539-542.
18. Franchini, G., M. Robert-Guroff, J. Tartaglia, A. Aggarwal, A. Abimiku, J. Benson, P. D. Markham, K. Limbach, G. Hurteau, J. Fullen, M. Wills, J. Arp, G. Dekaban, E. Paoletti, and R. C. Gallo. 1995. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11:909-920.
19. Gately, M., R. Chizzonite, and D. Presky. 1995. Measurement of human and mouse interleukin-12, p. 6.1.6-6.1.15. In J. Coligan et al. (ed.), Current protocols in immunology. Greene Publishing and Wiley-Interscience, New York, N.Y.
20. Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266.
21. Graham, B. S., T. J. Matthews, R. B. Bleshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. C. Keefer, D. P. Bolognesi, L. Corey, D. M. Stablein, J. R. Esterlitz, S.-L. Hu, G. E. Smith, P. E. Fast, N. C. Koff, and the NIAID AIDS Vaccine Clinical Trails Network. 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rpg160 in vaccinia-naive adults. J. Infect. Dis. 167:538-547.
22. Hirsch, M. S., and J. Curran. 1996. Human immunodeficiency viruses, p. 1953-1975. In B. N. Fields et al. (ed.), Fields virology. Lippincott-Raven, Philadelphia, Pa.
23. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
24. Hoffman, S. L., J. M. Crutcher, S. K. Puri, A. A. Ansari, F. Villinger, E. D. Franke, P. P. Singh, F. Finkelman, M. K. Gately, G. P. Dutta, and M. Sedegah. 1997. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat. Med. 3:80-83.
25. Hu, S.-L. 1994. Is subunit envelope antigen our best bet for an AIDS vaccine? p. 275-281. In M. Girard and B. Dodet (ed.), Neuvième Colloque des Cent Gardes. Retroviruses of human AIDS and related animal diseases. Marnes-La-Coquette, Paris, France.
26. Hussel, T., U. Khan, and P. Openshaw. 1997. IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness, J. Immunol. 159:328-334.
27. Jeannin, P., Y. Delnest, M. Seveso, P. Life, and J.-Y. Bonnefoy. 1996. IL-12 synergizes with IL-2 and other stimuli in inducing IL-10 production by human T cells. J. Immunol. 156:3159-3165.
28. Kawakita, M., G. S. Rao, J. K. Ritchey, D. K. Ornstein, D. K. Hudson, J. Tartaglia, E. Paoletti, P. A. Humphrey, T. J. Harmon, and T. L. Ratliff. 1997. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J. Natl. Cancer Inst. 89:428-436.
29. Lehner, T., Y. Wang, M. Cranage, L. A. Bergmeier, E. Mitchell, L. Tao, G. Hall, M. Denis, N. Cook, R. Brookes, L. Klavinskis, I. Jones, C. Doyle, and R. Ward. 1996. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelop and core vaccine in macaques. Nat. Med. 2:767-775.
30. Leno, M., L. Carter, L. Romano, P. D. Markham, K. Limbach, J. Tartaglia, E. Paoletti, J. Benson, G. Franchini, and M. Robert-Guroff. Vaccination-induced CD8 antiviral activity in rhesus macaques: correlation with low plasma viremia and slow disease progression following SIV challenge. Submitted for publication.
31. Leong, K. H., A. J. Ramsay, D. B. Boyle, and I. A. Ramshaw. 1994. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol. 68:8125-8130.
32. Lu, S., S. L. Arthos, D. C. Montefiori, Y. Yasutomi, K. Manson, F. Mustafa, E. Johnson, J. C. Santoro, J. Wissink, J. I. Mullins, J. R. Haynes, N. L. Letvin, M. Wyand, and H. L. Robinson. 1996. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3978-3991.
33. mac251 delta-3 in adult and infant rhesus monkeys. J. Immunol. 157:5528-5535.
34. Montefiori, D. C., G. Pantaleo, L. M. Fink, J. T. Zhou, J. Y. Zhou, M. Bilska, G. D. Miralles, and A. S. Fauci. 1996. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J. Infect. Dis. 173:60-67.
35. Myagkikh, M., S. Alipanah, P. D. Markham, J. Tartaglia, E. Paoletti, R. C. Gallo, G. Franchini, and M. Robert-Guroff. 1996. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12: 985-991.
36. Perkus, M. E., and E. Paoletti. 1996. Recombinant virus as vaccination carrier of heterologous antigens, p. 379-408. In S. H. E. Kaufmann (ed.), Concepts in vaccine development. Walter de Gruyter, Berlin, Germany.
37. Perkus, M. E., J. Tartaglia, and E. Paoletti. 1995. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukocyte Biol. 58:1-13.
38. Pialoux, G., J. L. Excler, Y. Riviere, G. Gonzalez-Canali, V. Feuillie, P. Coulaud, J. C. Gluckman, T. J. Matthews, B. Meignier, and M. P. Kieny, et al. 1995. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retroviruses 11; 373-381.
39. Romano, J. W., K. G. Williams, R. N. Shurtliff, C. Ginocchio, and M. Kaplan. 1997. NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol. Invest. 26:15-28.
40. Ruby, J., A. Ramshaw, G. Karupiah, and L. Ramshaw. 1992. Recombinant virus vectors that coexpress cytokines - a new vaccine strategy. Vaccine Res. 1:347-356.
41. Schultz, A. M., and S.-L. Hu. 1993. Primate models for HIV vaccines. AIDS 7(Suppl. 1):S161-170.
42. Schultz, A. M., and E. J. Stott. 1994. Primate models for AIDS vaccines. AIDS 8(Suppl. 1):S203-S212.
43. Seder, R. A., B. L. Kelsall, and D. Jankovic. 1996. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J. Immunol. 157:2745-2748.
44. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J.-C. Audonnet, W. I. Cox, S. W. Davis, J. Van Der Hoeven, B. Meignier, M. Riviere, B. Languet, and E. Paoletti. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
45. Taylor, J., C. Edbauer, A. Rey-Senelonge, J.-F. Bouquet, E. Norton, S. Goebel, P. Desmettre, and E. Paoletti. 1990. Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J. Virol. 64:1441-1450.
46. Vilinger, F., S. S. Brar, A. Mayne, N. Chikkala, and A. A. Ansari. 1995. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J. Immunol. 155:3946-3954.
47. Watson, A., J. Ranchalis, B. Travis, J. McClure, W. Sutton, P. R. Johnson, S.-H. Hu, and N. L. Haigwood. 1997. Plasma viremia in macaques infected with simian immunodeficiency virus: viral load early in infection predicts survival. J. Virol. 71:284-290.
48. Wolf, S. F., P. A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Lowe, R. Dzialo, L. Fitz, C. Ferenz, R. M. Hewick, K. Kelleher, S. H. Herrmann, S. C. Clark, L. Azzoni, S. H. Chan, G. Trinchieri, and B. Perussia. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effects on T and natural killer cells. J. Immunol. 146: 3074-3081.
49. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.
50. Wyand, M. S., K. H. Manson, A. A. Lackner, and R. C. Desrosiers. 1997. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat. Med. 3:32-36.